Article
Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.
Leukemia - 1 Apr 2020
Austin Rebecca J, Straube Jasmin, Bruedigam Claudia, Pali Gabor, Jacquelin Sebastien, Vu Therese, Green Joanne, Gräsel Julius, Lansink Lianne, Cooper Leanne, Lee Shin-Jye, Chen Nien-Tsu, Lee Chung-Wei, Haque Ashraful, Heidel Florian H, D'Andrea Richard, Hill Geoff R, Mullally Ann, Milsom Michael D, Bywater Megan, Lane Steven W
Abstract excerpt
JAK2V617F is the most common mutation in patients with BCR-ABL negative myeloproliferative neoplasms (MPNs). The eradication of JAK2V617F hematopoietic stem cells (HSCs) is critical for achieving molecular remissions and cure. We investigate the distinct effects of two therapies, ruxolitinib (JAK1/2 inhibitor) and interferon-alpha (IFN-α), on the disease-initiating HSC population. Whereas ruxolitinib inhibits...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.